HB 4453 creates the Oklahoma Health Care Cost Transparency Board to oversee a statewide health care data database (APCD) and measure spending trends. It requires commercial health insurers to report primary care spending data annually and meet a minimum 11% spending target on primary care by 2030, using a standardized methodology from the Oklahoma Health Care Authority. The bill mandates the Insurance Department to collect and analyze cost data from insurers, Medicaid, and Medicare, then publish annual transparency reports. Insurers failing to meet benchmarks face potential penalties up to $5,000 per day for noncompliance. This directly affects commercial health insurers operating in Oklahoma.
SB 207 establishes the Oklahoma Rare Disease Advisory Council within the State Department of Health to address the needs of Oklahomans living with rare diseases (defined as conditions affecting fewer than 200,000 people nationally). The Council, composed of 13 diverse members including patients, caregivers, healthcare providers, researchers, and industry representatives, will conduct public hearings, develop policy recommendations, and create emergency care protocols to improve access to specialists, diagnostics, and equitable treatment. The bill also modifies Oklahoma’s newborn screening program to require an educational initiative for treatable genetic disorders, aiming to prevent intellectual disabilities and reduce infant mortality through early intervention. This legislation directly affects rare disease patients, their families, healthcare providers, and state agencies responsible for public health programs in Oklahoma.
SB 1039 modifies Oklahoma's medical marijuana licensing system. It establishes a new Oklahoma Medical Marijuana Authority to process applications, sets a $100 biannual fee (or $20 for Medicaid/Medicare/SoonerCare users) for patient licenses, and creates three license types: standard two-year licenses, 60-day short-term licenses for patients with limited physician recommendations, and 30-day temporary licenses for out-of-state patients from regulated states. The bill requires the Authority to review applications within 14 business days and provide written denial reasons, while also creating caregiver licenses for homebound patients with specific limits. This law directly affects Oklahoma residents seeking medical marijuana access, out-of-state visitors with valid programs, and caregivers.
HB 2645 creates a tax credit for qualifying doctors practicing medicine in rural Oklahoma, directly affecting licensed physicians who meet specific residency and education criteria. The credit, capped at $20,000 per year per doctor, applies to taxable income from medical practice in designated rural areas (population under 25,000 and at least 25 miles from larger cities). The bill includes an annual $1 million total credit limit, with adjustments to prevent exceeding this cap. The bill was pocket-vetoed by the governor on June 15, 2025, and never became law.
HB 2262 requires nursing homes, assisted living facilities, and other care providers marketing specialized dementia care to publicly disclose detailed information about their services. Facilities must submit a standardized form to Oklahoma's State Department of Health, covering staff ratios, care plans, facility design, activities, fees, and family involvement - ensuring transparency for residents and families considering placement. The bill mandates posting this disclosure online and in facilities, with the Department reviewing it during inspections. It directly affects dementia care providers and supports informed decisions by families seeking appropriate care.
HB 1576 requires Oklahoma Medicaid to cover rapid whole genome sequencing (RWGS) for eligible beneficiaries under age 21 with complex or acute illnesses of unknown cause while receiving critical care in a hospital. It mandates coverage only when specific medical criteria are met, such as symptoms suggesting broad genetic testing needs, timely diagnosis being critical for treatment, and conditions like congenital anomalies or abnormal test results. The bill also ensures genetic data used for diagnosis is protected under HIPAA, allows research use only with explicit patient or guardian consent (with opt-out rights), and requires the Oklahoma Health Care Authority to implement rules and seek federal approval for coverage. This policy directly affects Medicaid-covered children and teens in intensive care with undiagnosed conditions.
HB 2584 allows physician assistants (PAs) in Oklahoma to prescribe and administer certain controlled substances under the supervision of a licensed physician, as specified in the Oklahoma Pharmacy Act and Physician Assistant Act. The bill clarifies that pharmacists may dispense these prescriptions only when written by a PA licensed in Oklahoma and supervised by an Oklahoma-licensed physician, and it modifies requirements for practice agreements between PAs and their supervising physicians. It also creates a 9-member Physician Assistant Committee with specific membership rules to oversee PA licensure and practice standards. The law directly affects PAs, supervising physicians, and pharmacists who dispense controlled substances. (Summary based on bill text amendments to Sections 353.1a, 519.2, and 519.3 of Oklahoma statutes.)
SB 804 requires Oklahoma assisted living centers to establish an internal quality assurance committee that meets quarterly. The committee must monitor incidents, resident satisfaction, and care quality - especially medication administration - and recommend policies, with membership including a registered nurse, administrator, direct care staff, and pharmacist as needed. The bill also updates existing rules to mandate monthly medication reviews by nurses/pharmacists, standardized resident screening, posting inspection results online, and individualized care plans. These changes directly affect all licensed assisted living centers in Oklahoma, effective November 1, 2025.
SB 574 expands the types of opioid-related projects eligible for state grant funding by allowing the Attorney General to allocate funds toward new prevention, treatment, and recovery initiatives. It directly affects state agencies and community organizations receiving opioid grants by broadening allowable uses beyond current restrictions. The bill authorizes the Attorney General to use grant funds for specific, previously ineligible activities, such as community-based support programs. This policy change modifies how opioid grant funds are distributed without altering the grant application process.
HB 2048, the "340B Nondiscrimination Act," prohibits health insurers, pharmacy benefits managers (PBMs), and third-party payors from discriminating against healthcare providers participating in the federal 340B drug discount program. It specifically bans lower reimbursement rates for 340B drugs, extra fees or administrative burdens for 340B entities, exclusion from provider networks based on 340B status, and requirements to disclose 340B-specific billing details. The law applies to all 340B entities - such as community health centers and hospitals participating in the federal program - and ensures they receive equal treatment in billing, reimbursement, and network access. Enforcement is handled by the Attorney General, with the Oklahoma Medicaid program excluded from these provisions.
